BioWorld

May 8, 2003

Study Of Memantine In Pain Misses Primary Endpoints

Negative trial news Wednesday sent ripples through companies involved in the development of memantine. (BioWorld Today) Read More

U.S. Genomics Raises $25M To Boost Detection Platform

Versatile Computer Program Helps Fabricate Useful Receptor Proteins That Bind Specific Structural Sites

Alfred Nobel (1833-1896), the world-famous chemist, engineer, industrialist and pacifist, made two lasting contrarian contributions to human civilization - dynamite and the Nobel Prize. Read More

Federal Reimbursement Rule Prompts Arguments From BIO

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 12, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 12, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Illustration of head with maze that is missing parts

CTAD 2025: The challenges of combination therapies for dementia

BioWorld Science

At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...

DEE-lightful: Praxis’ phase II results allow stock to flex its muscle

BioWorld

Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...